A team of U.S. and South Korean researchers have developed an AI model called MSI-SEER that can not only predict microsatellite instability-high (MSI-H) tumors based on tissue slides, but also flag “what it does not know.” “Have you ever asked ChatGPT anything, and the response was, ‘I don’t know?’” Cheong Jae-ho asked during an interview with BioWorld. “Probably not, and that is the problem with AI now.” Read More
Impaired fracture healing is a clinical management challenge. Fracture healing can be impaired due to several factors, such as aging, chronic inflammation or metabolic abnormalities. Osteoclasts play a crucial role in bone tissue reconstruction, but their abnormal activation can lead to impaired fracture healing. In a recent publication in Frontiers in Immunology, researchers from Naval Military Medical University and collaborators searched for crucial regulatory genes in the process of bone fracture healing. Read More
The FDA has cleared AD-NP1, a drug developed by University of California, Los Angeles (UCLA) for heart tissue regeneration, to enter clinical trials. The monoclonal antibody blocks the production of ENPP1 protein, which was found to interfere with healing after a heart attack. Read More
Researchers from Onco3r Therapeutics BV presented preclinical data on O3R-5671, a novel salt-inducible kinase 3 (SIK3) inhibitor developed for the treatment of inflammatory bowel disease and other autoimmune diseases. Read More
Chinese researchers have published preclinical data regarding the potential of never in mitosis A (NIMA)-related kinase 2 (NEK2) as a therapeutic target in multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system (CNS) in which B cells play a key role. Read More
BioWorld Staff Writer Randy Osborne reflects on the transformative progress in gene therapy – from tools like CRISPR and AAV vectors to major breakthroughs in diseases like hemophilia, sickle cell and beta-thalassemia. Read More
Beactica Therapeutics AB has held a first scientific advisory meeting with the Swedish Medical Products Agency (MPA) for BEA-17, the company’s first-in-class small-molecule targeted degrader of lysine demethylase 1 (LSD1) and its co-factor CoREST. Read More
Arcus Biosciences Inc. has announced five new research programs for autoimmune and inflammatory diseases, and is targeting initiation of the first clinical studies next year. Read More
Muna Therapeutics ApS has patented new triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes and obesity, among others. Read More
Work at Pharmaengine Inc. has led to the identification of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer. Read More
Individuals with the inherited disorder Fanconi anemia cannot properly repair damage to their DNA, increasing risk of cancers such as head and neck squamous cell carcinoma (HNSCC). Read More
Domain Therapeutics SA has prepared and tested new azine-based compounds acting as proteinase-activated receptor 2 (F2RL1; PAR2) inhibitors reported to be useful for the treatment of allergy, autoimmune, metabolic diseases, cardiovascular, dermatological, inflammatory disorders, pain and cancer. Read More
Washington University in St. Louis has disclosed new autophagy inducers reported to be useful for the treatment of alpha-1 antitrypsin deficiency, amyotrophic lateral sclerosis, Alzheimer’s, Huntington’s and Parkinson’s disease. Read More
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumor in adults, marked by high treatment resistance and poor prognosis. OLIG2, a CNS-specific transcription factor essential for neural development, is highly expressed in GBM and contributes to tumor progression and therapy resistance, making it a promising target for novel therapeutic strategies. Read More
